Generics Bulletin Explains: The Next Wave of US Humira Biosimilars

Humira ― for a long time the world’s top-selling drug, and still one of the biggest brands in the business – finally faced US biosimilar competition this year, with Amgen at the end of January launching the first of many adalimumab biosimilars approved by the US Food and Drug Administration. A multitude of other competitors are bringing further adalimumab biosimilars to the US market, as per the terms of their individual litigation settlements with originator AbbVie.